Evidence map›Paper›PMID 9453638›Full record

ArticleInfection and immunity1998

Increased resistance to Taenia crassiceps murine cysticercosis in Qa-2 transgenic mice.

G Fragoso, E Lamoyi, A Mellor, C Lomelí, M Hernández, E Sciutto

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 65 citations in OpenAlex.

  1. Infection and immunity · 2023
    Article
  2. Differential Protein Expression ofPathogens (Basel, Switzerland) · 2023
    Article
  3. Pathogens (Basel, Switzerland) · 2023
    Article
  4. Regulatory T Cells as an Escape Mechanism to the Immune Response inFrontiers in cellular and infection microbiology · 2021
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Promiscuity of MHC class Ib-restricted T cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2003
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

G FragosoDepartment of Immunology, Instituto de Investigaciones Biomédicas, UNAM, México D.F., México.
E Lamoyi
A Mellor
C Lomelí
M Hernández
E Sciutto
Augusta University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported important differences in resistance to Taenia crassiceps murine cysticercosis between BALB/c substrains. It was suggested that resistance might correlate with expression of the nonclassic class I major histocompatibility complex (MHC) Qa-2 antigen; BALB/cAnN is Qa-2 negative and highly susceptible to T. crassiceps, whereas BALB/cJ expresses Qa-2 and is highly resistant. In this study, we investigated the role of Qa-2 in mediating resistance to cysticercosis by linkage analysis and infection of Qa-2 transgenic mice. In BALB/cAnN x (C57BL/6J x BALB/cAnN)F1 and BALB/cAnN x (BALB/cJ x BALB/cAnN)F1 backcrosses, the expression of Qa-2 antigen correlated with resistance to cysticercosis. Significantly fewer parasites were recovered from infected Qa-2 transgenic male and female mice than from nontransgenic mice of similar genetic background. These results clearly demonstrate that the Qa-2 MHC antigen is involved in resistance to T. crassiceps cysticercosis.

Indexed as

AnimalsCysticercosisFemaleHistocompatibility Antigens Class IMaleMiceMice, Inbred StrainsMice, TransgenicSex FactorsSpecies SpecificityHistocompatibility Antigens Class IQ surface antigens

Identifiers

PMID9453638
PMCPMC107967
OpenAlexW1947203310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.